Aptevo therapeutics inc. (APVO)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15
Operating expenses:
Revenues:
Product sales

32,424

23,067

14,658

-

-

Product sales

-

-

-

9,805

27,947

Collaborations

-

-

-

180

5,654

Total revenues

-

-

-

9,985

33,601

Costs and expenses:
Cost of product sales

19,927

11,214

-

-

-

Cost of product sales

-

-

-

12,467

16,933

Research and development

29,757

35,385

29,021

29,120

34,726

Selling, general and administrative

25,336

28,133

34,576

36,158

43,042

Impairment of goodwill and intangible assets

-

-

-

71,013

-

Loss from operations

-42,596

-51,665

-53,949

-138,773

-61,100

Other expense:
Other expense, net

-2,102

-2,024

-1,944

-810

-237

Total other expense

-

-

-

-810

-237

Loss before income tax

-

-

-55,893

-139,583

-61,337

Benefit from income tax

-

-

-23,301

-19,692

-2,020

Net loss from continuing operations

-44,698

-53,689

-32,592

-119,891

-

Discontinued operations (Note 2):
Income from discontinued operations, before income taxes

-

-

62,864

11,828

-

Income tax expense

-

-

23,299

4,352

-

Income (loss) from discontinued operations

4,250

-

39,565

7,476

-

Net income (loss)

-40,448

-53,689

6,973

-112,415

-59,317

Basic and diluted net income (loss) per share:
Net loss from continuing operations

-1.09

-2.39

-1.53

-5.92

-

Net income (loss) from discontinued operations

0.10

-

1.86

0.37

-

Basic and diluted net income (loss) per basic share

-0.99

-2.39

0.33

-5.55

-2.93

Weighted-average shares used to compute per share calculations

40,838

22,500

21,335

20,239

20,229

Product sales
Total revenues

-

-

10,949

-

-

Cost of product sales

-

-

5,010

-

-

Collaborations
Total revenues

-

-

3,709

-

-